The Wegovy pill is a daily tablet version of the semaglutide medication that has been widely used in injectable form for weight management and metabolic health. This oral formulation was approved by the FDA in late 2025 and became available in pharmacies across the United States. It gives people who prefer not to use injections an alternative way to take the same active ingredient.
A common concern is how much the Wegovy pill costs per month without insurance and how that expense compares with the injectable version. This guide will break down the monthly out-of-pocket cost of the new Wegovy pill and explain the factors that influence these prices.
How much does the Wegovy pill cost without insurance?
According to Novo Nordisk’s official pricing information, the list price for Wegovy tablets is $1,349.02 for a 30-tablet bottle. This price applies across all tablet strengths, including 1.5 mg, 4 mg, 9 mg, and 25 mg.
However, Novo Nordisk also promotes a much lower self-pay option for people paying out of pocket. Under this program, monthly pricing starts at $149 for the 1.5 mg tablet and increases to $299 per month for the 9 mg and 25 mg doses. The 4 mg tablet is offered at $149 per month for new patients through April 15, 2026, after which the price increases to $199 per month.
You can access these self-pay prices through select channels, including:
-
- NovoCare Pharmacy
- Amazon Pharmacy
- Costco
- GoodRx
Outside of these manufacturer-supported programs, you will likely pay the full list price. In that case, the monthly cost of the Wegovy pill is essentially the same as the injection, at about $1,349 for a one-month supply.
How much does the Wegovy pill cost with insurance?
If you have commercial insurance and qualify for the manufacturer savings offer, your monthly cost for the Wegovy pill can be as low as $25. The exact amount you pay still depends on how your specific insurance plan covers weight-management medications, including whether prior authorization, step therapy, or other limits apply.
Historically, many health insurers have excluded coverage for weight loss medications. Obesity treatment has often been classified as nonessential or too expensive to include in standard benefit plans.
If you rely on Medicare, coverage is not available. Federal law prevents Medicare from paying for medications used specifically for weight loss, even though obesity is widely recognized as a chronic medical condition.
Medicaid coverage depends on where you live. In early 2025, at least 13 states added coverage for Wegovy or similar medications under their Medicaid plans. Some private insurers have also expanded coverage as evidence of broader health benefits has grown, particularly after Wegovy received FDA approval to reduce cardiovascular risk.
If your insurance does not cover Wegovy, manufacturer savings programs become especially important. Options such as the $149 per month Wegovy pill program or the $349 per month injection pricing can significantly lower your out-of-pocket cost compared with paying full list price.
Comparing the monthly costs of the Wegovy pill vs. injection
If you use manufacturer-supported programs, the Wegovy pill is likely to cost much less per month than the Wegovy injection, especially at the start of treatment. At the initial dose, the pill is priced at $149 per month, which is less than half of the injection’s current discounted price of $349. Even as the pill dose increases, its monthly cost generally remains below the injection price.
If you are not using these programs, you will likely pay the full list price. In that situation, the monthly cost of the Wegovy pill is essentially the same as the injection, at about $1,349 for a one-month supply.
One reason for this pricing difference is how the medications are made and distributed. Oral medications are typically cheaper to produce than injectable drugs. Wegovy injections are delivered in prefilled pens that require complex manufacturing, sterile liquid formulation, and refrigerated shipping throughout the supply chain.
The Wegovy pill does not need refrigeration, is easier to store and transport, and does not require an injection device. Because of this, Novo Nordisk likely faces lower production and distribution costs per dose for the pill compared with the injection, which helps support lower pricing while preserving profitability.
Why are these medications so expensive?
Several factors influence this, including how the drug works, how it is manufactured and priced, and how insurance coverage and healthcare policies shape access.
Research and development costs
Drug companies often cite R&D expenses to justify high prices. In the case of semaglutide for obesity, multiple Phase 3 trials were conducted globally to establish safety and efficacy. These trials, spanning over a year for each patient, require significant investment. The cost must be recouped through sales, and initially, that meant a high price point for Wegovy.
A report from the Institute for Clinical and Economic Review (ICER) in 2022 acknowledged the impressive efficacy of semaglutide but noted it would only be cost-effective if priced around $7,500-$9,800 per year (roughly $625-$817 per month) under typical US cost-effectiveness thresholds.
The original list price for Wegovy, which was close to $16,000 per year, sat well above that range. Health policy experts have since noted that while GLP-1 medications offer meaningful health improvements, their initial prices were far above commonly accepted cost-effectiveness thresholds. That disconnect helped drive pressure from payers and policymakers to push for lower pricing over time.
Manufacturing and formulation
As noted earlier, the injectable form involves complex manufacturing. Each Wegovy pen combines the medication, the delivery device, and protective packaging, all of which must preserve sterility and drug stability. These requirements add to production and distribution costs.
The oral form of semaglutide was not simple to develop either. Semaglutide is a peptide that would normally be broken down by stomach acids. To make an effective pill, Novo Nordisk had to include a specialized absorption enhancer and require strict dosing instructions, such as taking the tablet on an empty stomach. This approach is similar to how oral semaglutide is used in diabetes treatment.
Even with these added steps, producing tablets is generally less expensive than manufacturing injectable pens. Because the oral version is still new, Novo Nordisk likely approached pricing carefully. Setting the price too low could have undercut the injectable option and frustrated patients already paying more for injections.
At the same time, pricing the pill lower than injections helps attract new users and expand access without fully disrupting the existing market.
Insurance coverage gaps
When a medication is covered by insurance, you usually do not pay the full list price. Drug companies negotiate rebates with insurers, which lowers what most patients actually pay. With weight loss medications like Wegovy, that system did not work the same way at first.
Many insurance plans initially refused to cover Wegovy or set very strict requirements. Weight loss was often treated as a lifestyle issue rather than a medical condition. With so many patients paying cash, the cost shifted directly to consumers.
As long as enough people were willing to pay high out-of-pocket prices because the drug worked and options were limited, prices stayed high. Broader efforts to lower costs did not gain momentum until public attention and political pressure increased as obesity treatment became a national issue.
Market competition
Until late 2023, Novo Nordisk largely dominated the obesity drug market. Wegovy was the only medication approved specifically for weight loss that consistently delivered around 15% average body weight reduction in clinical trials. Its sister drug, Ozempic, which contains the same active ingredient, was also widely used off-label for weight loss during this period.
That changed in late 2023, when Eli Lilly received approval for tirzepatide for obesity, branded as Zepbound. Clinical trials showed higher average weight loss with tirzepatide, often around 20% or more. This increased pressure on Novo Nordisk to respond, not just by developing new options like the Wegovy pill, but also by rethinking pricing.
More competitors are in development, including oral weight loss drugs from Eli Lilly and obesity treatments being studied by Pfizer and Amgen. As more products enter the market, you can expect stronger price competition.
High demand and no generic competition
Wegovy treats a condition that affects a very large portion of the population. More than 40% of US adults meet the clinical definition of obesity. When Wegovy demonstrated strong weight loss results in clinical trials, demand rose rapidly. When demand is high and supply is limited, manufacturers are often able to maintain higher prices.
Patent protection also contributes. At present, there is no lower-cost generic version of semaglutide approved for obesity treatment. Novo Nordisk holds patents covering both the drug itself and its approved uses for weight management. Based on available patent and exclusivity data, generic semaglutide tablets for obesity are unlikely to reach the US market until around 2033. Generic injectable versions also appear to have several years of patent protection remaining.
How to lower your out-of-pocket costs for Wegovy tablets
Here are some tips to potentially save on Wegovy:
Use the manufacturer’s programs
Novo Nordisk’s NovoCare and other programs are currently the primary way to get Wegovy at the discounted rates. Make sure your doctor or pharmacist knows you’ll be paying out of pocket, so they can help you enroll in any available savings program.
Novo Nordisk has an online portal where you can get a coupon or enrollment code for the self-pay offer, such as the first two months at $199 for injections, or access to the pill at $149. These often require a prescription and some basic patient information, but not insurance.
Telehealth subscription services
Some telehealth weight management services offer monthly subscriptions that include the medication, medical oversight, and sometimes lifestyle coaching. Prices can vary, but some advertise costs that effectively bring the medication price down.
Ensure any such service is reputable. Ideally, one affiliated with known healthcare providers or programs. These services might also offer the convenience of home delivery.
Patient assistance programs
If your income is very limited, Novo Nordisk has a patient assistance program that, in some cases, can provide the medication at low or no cost. These typically have strict eligibility criteria, such as no insurance and income below a certain threshold. Information on these programs can usually be found on the manufacturer’s website or through advocacy organizations.
Stay informed on coverage changes
There’s growing recognition that treating obesity can prevent costly diseases. In fact, federal legislation like the Treat and Reduce Obesity Act has been proposed to allow Medicare to cover weight-loss medications, though it hasn’t passed yet.
Some employers are starting to add coverage due to employee demand. As these drugs become more common, insurers might soften their stance. Check in with your insurer each year.
Alternative medications
Wegovy is not the only weight-loss medication, though it is the most effective of the new generation. There are older drugs like phentermine, and other GLP-1s like Saxenda (liraglutide, a daily injection), which is another GLP-1 for weight loss. It’s somewhat less effective and also expensive, but it goes off-patent sooner and could have a generic in a few years, possibly reducing cost.
Eli Lilly is also developing an oral weight loss drug called orforglipron, which is expected to reach the market around mid-2026. Early trial results suggest it may lead to less average weight loss than the Wegovy pill. If that gap holds, Lilly may choose to price the pill lower to attract patients who prefer oral treatment but are more sensitive to cost.
Beyond Lilly, more weight loss drugs are in development, including combination therapies and newer multi-agonist medications. As these options reach the market, you may see broader choices and stronger price competition, especially for patients who find Wegovy too expensive.
Bottom line
The Wegovy pill can be expensive without insurance, with a list price of about $1,349 per month. However, manufacturer self-pay programs significantly lower real-world costs for many patients, with monthly prices starting at $149 when accessed through approved channels. Without these programs, the pill costs roughly the same as the injection.
Insurance coverage remains inconsistent. Some commercially insured patients may pay as little as $25 per month, while Medicare offers no coverage, and Medicaid access varies by state. Until broader coverage and competition arrive, manufacturer savings programs remain the most reliable way to reduce out-of-pocket costs for Wegovy tablets.
Related Articles
Frequently Asked Questions
Sources
Wegovy® (semaglutide) tablet 25 mg, injection 2.4 mg Cost, Coverage, & Savings Resources | NovoCare®. (n.d.). https://www.novocare.com/patient/medicines/wegovy.html
ICER. (2023, December 22). Obesity Management – ICER. https://icer.org/assessment/obesity-management-2022/
What will I pay? (n.d.). https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
